CytomX Therapeutics (CTMX) Stock Price, News & Analysis

Company Overview

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $2.22 to $2.39
• 50-Day Range: $0.65 to $2.99
• 52-Week Range: $0.40 to $3.10
• Volume: 2.26 million shs
• Average Volume: 2.19 million shs
• Market Capitalization: $183.01 million
• P/E Ratio: 4.73
• Dividend Yield: N/A
• Price Target: $5.33
• Consensus Rating: Buy

CytomX Therapeutics Stock Analysis - MarketRank™

CytomX Therapeutics scored higher than 85% of companies evaluated by MarketBeat, and ranked 152nd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

CytomX Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

CytomX Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.05) to ($0.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CytomX Therapeutics is 4.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.90.

Price to Earnings Ratio vs. Sector

The P/E ratio of CytomX Therapeutics is 4.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.46.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

27.61% of the float of CytomX Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CytomX Therapeutics has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in CytomX Therapeutics has recently increased by 9.65%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CytomX Therapeutics does not currently pay a dividend.

Dividend Growth

CytomX Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.74

Percentage of Shares Shorted

27.61% of the float of CytomX Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CytomX Therapeutics has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in CytomX Therapeutics has recently increased by 9.65%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.24

News Sentiment

CytomX Therapeutics has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for CytomX Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 14 people have searched for CTMX on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.

MarketBeat Follows

3 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CytomX Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.60% of the stock of CytomX Therapeutics is held by insiders.

Percentage Held by Institutions

67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CTMX Stock Analysis - Frequently Asked Questions

How have CTMX shares performed this year?

CytomX Therapeutics' stock was trading at $1.03 at the beginning of the year. Since then, CTMX shares have increased by 120.4% and is now trading at $2.27.
View the best growth stocks for 2025 here.

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) posted its quarterly earnings data on Monday, May, 12th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.09. The biotechnology company earned $50.92 million during the quarter, compared to the consensus estimate of $35.42 million. CytomX Therapeutics had a negative trailing twelve-month return on equity of 553.71% and a net margin of 28.22%.
Read the conference call transcript.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CytomX Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), CymaBay Therapeutics (CBAY), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 6/30/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CTMX
• CIK: 1501989
• Web: www.cytomx.com
• Phone: (605) 515-3185
• Fax: 650-351-0353
• Employees: 170
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.33
• High Stock Price Target: $6.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +134.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.48
• Trailing P/E Ratio: 4.73
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $31.87 million
• Net Margins: 28.22%
• Pretax Margin: 28.35%
• Return on Equity: -553.71%
• Return on Assets: 32.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.73
• Quick Ratio: 1.73

Sales & Book Value

• Annual Sales: $147.56 million
• Price / Sales: 1.24
• Cash Flow: $0.36 per share
• Price / Cash Flow: 6.22
• Book Value: ($0.01) per share
• Price / Book: -227.00

Miscellaneous

• Outstanding Shares: 80,621,000
• Free Float: 75,300,000
• Market Cap: $183.01 million
• Optionable: Optionable
• Beta: 2.11